Background: Emerging evidence argues that monocytes, circulating innate immune cells, are principal players in COVID-19 pneumonia. The study aimed to investigate the role of soluble (s)CD163 and sCD14 plasmatic levels in predicting disease severity and characterize peripheral blood monocytes and dendritic cells (DCs), in patients with COVID-19 pneumonia (COVID-19 subjects). Methods: On admission, in COVID-19 subjects sCD163 and sCD14 plasmatic levels, and peripheral blood monocyte and DC subsets were compared to healthy donors (HDs). According to clinical outcome, COVID-19 subjects were divided into ARDS and non-ARDS groups. Results: Compared to HDs, COVID-19 subjects showed higher sCD163 (p<0.0001) and sCD14 (p<0.0001) plasmatic levels. We observed higher sCD163 plasmatic levels in the ARDS group compared to the non-ARDS one (p=0.002). The cut-off for sCD163 plasmatic level greater than 2032 ng/ml was predictive of disease severity (AUC: 0.6786, p=0.0022; sensitivity 56.7% [CI: 44.1-68.4] specificity 73.8% [CI: 58.9-84.7]). Positive correlation between plasmatic levels of sCD163, LDH and IL-6 and between plasmatic levels of sCD14, D-dimer and ferritin were found. Compared to HDs, COVID-19 subjects showed lower percentages of non-classical (p=0.0012) and intermediate monocytes (p=0.0447), slanDCs (p<0.0001), myeloid DCs (mDCs, p<0.0001), and plasmacytoid DCs (pDCs, p=0.0014). Compared to the non-ARDS group, the ARDS group showed lower percentages of non-classical monocytes (p=0.0006), mDCs (p=0.0346), and pDCs (p=0.0492). Conclusions: The increase in sCD163 and sCD14 plasmatic levels, observed on hospital admission in COVID-19 subjects, especially in those who developed ARDS, and the correlations of these monocyte/macrophage activation markers with typical inflammatory markers of COVID-19 pneumonia, underline their potential use to assess the risk of progression of the disease. In an early stage of the disease, the assessment of sCD163 plasmatic levels could have clinical utility in predicting the severity of COVID-19 pneumonia.
Background: Emerging evidence argues that monocytes, circulating innate immune cells, are principal players in COVID-19 pneumonia. The study aimed to investigate the role of soluble (s)CD163 and sCD14 plasmatic levels in predicting disease severity and characterize peripheral blood monocytes and dendritic cells (DCs), in patients with COVID-19 pneumonia (COVID-19 subjects). Methods: On admission, in COVID-19 subjects sCD163 and sCD14 plasmatic levels, and peripheral blood monocyte and DC subsets were compared to healthy donors (HDs). According to clinical outcome, COVID-19 subjects were divided into ARDS and non-ARDS groups. Results: Compared to HDs, COVID-19 subjects showed higher sCD163 (p<0.0001) and sCD14 (p<0.0001) plasmatic levels. We observed higher sCD163 plasmatic levels in the ARDS group compared to the non-ARDS one (p=0.002). The cut-off for sCD163 plasmatic level greater than 2032 ng/ml was predictive of disease severity (AUC: 0.6786, p=0.0022; sensitivity 56.7% [CI: 44.1-68.4] specificity 73.8% [CI: 58.9-84.7]). Positive correlation between plasmatic levels of sCD163, LDH and IL-6 and between plasmatic levels of sCD14, D-dimer and ferritin were found. Compared to HDs, COVID-19 subjects showed lower percentages of non-classical (p=0.0012) and intermediate monocytes (p=0.0447), slanDCs (p<0.0001), myeloid DCs (mDCs, p<0.0001), and plasmacytoid DCs (pDCs, p=0.0014). Compared to the non-ARDS group, the ARDS group showed lower percentages of non-classical monocytes (p=0.0006), mDCs (p=0.0346), and pDCs (p=0.0492). Conclusions: The increase in sCD163 and sCD14 plasmatic levels, observed on hospital admission in COVID-19 subjects, especially in those who developed ARDS, and the correlations of these monocyte/macrophage activation markers with typical inflammatory markers of COVID-19 pneumonia, underline their potential use to assess the risk of progression of the disease. In an early stage of the disease, the assessment of sCD163 plasmatic levels could have clinical utility in predicting the severity of COVID-19 pneumonia.
Authors: Nicholas T Funderburg; David A Zidar; Carey Shive; Anthony Lioi; Joseph Mudd; Laura W Musselwhite; Daniel I Simon; Marco A Costa; Benigno Rodriguez; Scott F Sieg; Michael M Lederman Journal: Blood Date: 2012-10-11 Impact factor: 22.113
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Geidy E Serrano; Jessica E Walker; Cécilia Tremblay; Ignazio S Piras; Matthew J Huentelman; Christine M Belden; Danielle Goldfarb; David Shprecher; Alireza Atri; Charles H Adler; Holly A Shill; Erika Driver-Dunckley; Shyamal H Mehta; Richard Caselli; Bryan K Woodruff; Chadwick F Haarer; Thomas Ruhlen; Maria Torres; Steve Nguyen; Dasan Schmitt; Steven Z Rapscak; Christian Bime; Joseph L Peters; Ellie Alevritis; Richard A Arce; Michael J Glass; Daisy Vargas; Lucia I Sue; Anthony J Intorcia; Courtney M Nelson; Javon Oliver; Aryck Russell; Katsuko E Suszczewicz; Claryssa I Borja; Madison P Cline; Spencer J Hemmingsen; Sanaria Qiji; Holly M Hobgood; Joseph P Mizgerd; Malaya K Sahoo; Haiyu Zhang; Daniel Solis; Thomas J Montine; Gerald J Berry; Eric M Reiman; Katharina Röltgen; Scott D Boyd; Benjamin A Pinsky; James L Zehnder; Pierre Talbot; Marc Desforges; Michael DeTure; Dennis W Dickson; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2022-08-16 Impact factor: 3.148
Authors: Alexandra Melton; Lara A Doyle-Meyers; Robert V Blair; Cecily Midkiff; Hunter J Melton; Kasi Russell-Lodrigue; Pyone P Aye; Faith Schiro; Marissa Fahlberg; Dawn Szeltner; Skye Spencer; Brandon J Beddingfield; Kelly Goff; Nadia Golden; Toni Penney; Breanna Picou; Krystle Hensley; Kristin E Chandler; Jessica A Plante; Kenneth S Plante; Scott C Weaver; Chad J Roy; James A Hoxie; Hongmei Gao; David C Montefiori; Joseph L Mankowski; Rudolf P Bohm; Jay Rappaport; Nicholas J Maness Journal: PLoS Pathog Date: 2021-12-20 Impact factor: 6.823
Authors: Amelia C Trombetta; Guilherme B Farias; André M C Gomes; Ana Godinho-Santos; Pedro Rosmaninho; Carolina M Conceição; Joel Laia; Diana F Santos; Afonso R M Almeida; Catarina Mota; Andreia Gomes; Marta Serrano; Marc Veldhoen; Ana E Sousa; Susana M Fernandes Journal: Front Immunol Date: 2021-06-23 Impact factor: 7.561
Authors: María Luisa Rodríguez de la Concepción; Erola Ainsua-Enrich; Esteban Reynaga; Carlos Ávila-Nieto; Jose Ramón Santos; Silvia Roure; Lourdes Mateu; Roger Paredes; Jordi Puig; Juan Manuel Jimenez; Nuria Izquierdo-Useros; Bonaventura Clotet; María Luisa Pedro-Botet; Jorge Carrillo Journal: Life Sci Alliance Date: 2021-07-28